Eculizumab is a recombinant humanized monoclonal IgG2/4 antibody that binds specifically to complement protein C5 inhibiting its cleavage to C5a and C5b preventing the formation of the terminal complex (MAC). The role of this expensive medication in transplantation requires further study.[9, 10] In summary, this case illustrates that genetic abnormalities in the complement regulatory proteins may be associated with severe, uncontrolled antibody-mediated rejection and contribute to the poor graft outcome in patients with aHUS in the absence of haematological changes of TMA. “
“Aim:  Vitamin D analogues, cinacalcet, and sevelamer

play pivotal roles in the management of chronic kidney disease-mineral bone disorder, and are noted to have pleiotropic effects. We examined whether these agents might be associated with the responsiveness to erythropoiesis-stimulating agents RG7204 research buy (ESA). Methods:  In this cross-sectional study including haemodialysis patients treated with ESA, we searched for clinical parameters associated with the ESA resistance index, which was calculated as the selleck inhibitor weekly ESA dose divided by the patient’s haemoglobin value. Results:  Among 45 patients (male: female = 28 : 17, age 68 ± 10 years, haemodialysis duration 84 ± 60 months), vitamin D analogue, cinacalcet, and sevelamer were used in 95.6%, 26.7%, and 84.4%

of the patients, respectively. Univariate analysis showed significant association of the ESA resistance index with transferrin saturation rate (TSAT), vitamin D analogue dose, and sevelamer dose. In multivariate analysis, the sevelamer dose and TSAT were found to be independent determinants of the ESA resistance index. Conclusion:  Our preliminary data showed an independent association between sevelamer Sulfite dehydrogenase dose and the responsiveness to ESA in haemodialysis patients. Further studies are required to investigate the causal relationship between

sevelamer and ESA responsiveness. “
“Most clinical registries in Australia, including the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), do not audit submitted data. Inaccurate data can bias registry analysis. This study aimed to audit data submitted to ANZDATA from a single region. A retrospective audit of individual haemodialysis patient data recorded by ANZDATA at 31 December 2009 was completed by nephrologists in a blinded fashion. Original data were recorded by nursing staff. Patients received treatment at a public hospital, two affiliated satellite haemodialysis units, and three private haemodialysis units. Fifty-one audits were completed of a total 175 patients (29.1%) undertaking haemodialysis in 2009. Primary renal disease was correct in 86.3% (95%CI: 74.3–93.2), although errors in type of glomerulonephritis were common.